

# Naoya Yamazaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7007286/publications.pdf>

Version: 2024-02-01

63  
papers

4,558  
citations

361296

20  
h-index

133188

59  
g-index

63  
all docs

63  
docs citations

63  
times ranked

6291  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part). <i>Supportive Care in Cancer</i> , 2022, 30, 4497-4504. | 1.0 | 2         |
| 2  | The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .   | 0.6 | 3         |
| 3  | Prognostic factor analysis of definitive radiotherapy using intensity-modulated radiation therapy and volumetric modulated arc therapy with boluses for scalp angiosarcomas. <i>Scientific Reports</i> , 2022, 12, 4355.  | 1.6 | 5         |
| 4  | Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of <sc>JCOG2005</sc> (<sc>Jâ€BASEâ€MARGIN</sc>). <i>Journal of Dermatology</i> , 2022, 49, 837-844.  | 0.6 | 1         |
| 5  | Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a postâ€marketing surveillance. <i>Journal of Dermatology</i> , 2022, 49, 862-871.  | 0.6 | 6         |
| 6  | Case of acquired reactive perforating collagenosis induced by panitumumab for colon cancer. <i>Journal of Dermatology</i> , 2021, 48, e114-e115.  | 0.6 | 4         |
| 7  | Clinical response to a MEK inhibitor in a patient with metastatic melanoma harboring an <i>RAF1</i> gene rearrangement detected by cancer gene panel testing. <i>Journal of Dermatology</i> , 2021, 48, e256-e257.  | 0.6 | 5         |
| 8  | Fiveâ€year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Journal of Dermatology</i> , 2021, 48, 592-599.  | 0.6 | 10        |
| 9  | A review of the AJCC melanoma staging system in the TNM classification (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 671-674.  | 0.6 | 8         |
| 10 | Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial. <i>Journal of Dermatology</i> , 2021, 48, 1077-1080.   | 0.6 | 2         |
| 11 | Two cases of advanced cutaneous squamous cell carcinoma lesions on the head and neck successfully treated with nivolumab. <i>Journal of Dermatology</i> , 2021, 48, e434-e435.  | 0.6 | 0         |
| 12 | Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study). <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1232-1241.  | 0.6 | 9         |
| 13 | Efficacy of surgery for skin cancers initially suspected to be carcinoma of unknown primary: a retrospective observational study. <i>International Journal of Dermatology</i> , 2021, , .   | 0.5 | 0         |
| 14 | Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. <i>Cancer Science</i> , 2021, 112, 4748-4757.  | 1.7 | 9         |
| 15 | Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. <i>European Journal of Cancer</i> , 2021, 157, 361-372.   | 1.3 | 24        |
| 16 | Bullous pemphigoid induced by pembrolizumab in a patient with nonâ€smallâ€cell lung cancer who achieved durable complete response despite treatment cessation and longâ€term corticosteroid administration: A case report. <i>Journal of Dermatology</i> , 2020, 47, e9-e11.  | 0.6 | 6         |
| 17 | Secretory carcinoma of the skin arising on the eyelid, distinguished by immunohistochemical markers and fluorescence <i>in situ</i> hybridization. <i>Journal of Dermatology</i> , 2020, 47, e99-e100.  | 0.6 | 4         |
| 18 | Realâ€world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutationâ€positive advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 257-264.   | 0.6 | 10        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Case of multiple ectopic extramammary Paget's disease of the trunk. <i>Journal of Dermatology</i> , 2020, 47, e329-e331.   | 0.6 | 1         |
| 20 | A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol). <i>BMC Cancer</i> , 2020, 20, 652.   | 1.1 | 4         |
| 21 | Absence of toxic epidermal necrolysis recurrence with pembrolizumab rechallenge in a patient with a positive lymphocyte transformation test. <i>Journal of Dermatology</i> , 2020, 47, e424-e425.                            | 0.6 | 3         |
| 22 | Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 1267-1275.  | 0.6 | 15        |
| 23 | Anti-PD-1 antibody therapy for epithelial skin malignancies. <i>Medicine (United States)</i> , 2020, 99, e22913.   | 0.4 | 6         |
| 24 | Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naïve advanced melanoma. <i>Journal of Dermatology</i> , 2020, 47, 1257-1266.                                   | 0.6 | 16        |
| 25 | Fixed drug eruption dramatically exacerbated during treatment with programmed death 1 inhibitor. <i>Journal of Dermatology</i> , 2020, 47, e425-e426.  | 0.6 | 1         |
| 26 | Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. <i>Journal of Dermatology</i> , 2020, 47, 834-848.                           | 0.6 | 14        |
| 27 | Outcomes of lymph node dissection in the treatment of extramammary Paget's disease: A single-institution study. <i>Journal of Dermatology</i> , 2020, 47, 512-517.   | 0.6 | 8         |
| 28 | Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review. <i>Dermatologic Therapy</i> , 2020, 33, e13321.                            | 0.8 | 16        |
| 29 | Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. <i>Journal of Dermatology</i> , 2020, 47, 622-628.                  | 0.6 | 10        |
| 30 | Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used. <i>European Journal of Cancer</i> , 2020, 127, 108-117.                                     | 1.3 | 14        |
| 31 | Japanese real-world study of sequential nivolumab and ipilimumab treatment in melanoma. <i>Journal of Dermatology</i> , 2019, 46, 947-955.   | 0.6 | 11        |
| 32 | Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III / IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study. <i>Journal of Dermatology</i> , 2019, 46, 1197-1201. | 0.6 | 13        |
| 33 | Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.  | 1.3 | 79        |
| 34 | Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma. <i>Cancer Science</i> , 2019, 110, 1995-2003.  | 1.7 | 31        |
| 35 | Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. <i>Journal of Dermatology</i> , 2019, 46, 498-506.                               | 0.6 | 13        |
| 36 | Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption. <i>Journal of Dermatology</i> , 2019, 46, 18-25.     | 0.6 | 8         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 37 | Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab. <i>Journal of Dermatology</i> , 2019, 46, e178-e180.   | 0.6  | 7         |
| 38 | Real-world efficacy of anti-PD-1 antibodies in advanced acral melanoma patients: A retrospective, multicenter study (JAMP study).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9529-9529.   | 0.8  | 4         |
| 39 | Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. <i>Journal of Dermatology</i> , 2018, 45, 408-415.  | 0.6  | 38        |
| 40 | Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma. <i>Journal of Dermatology</i> , 2018, 45, 397-407.                                    | 0.6  | 22        |
| 41 | Surgery with curative intent is associated with prolonged survival in patients with cutaneous angiosarcoma of the scalp and face -a retrospective study of 38 untreated cases in the Japanese population. <i>European Journal of Surgical Oncology</i> , 2018, 44, 823-829. | 0.5  | 18        |
| 42 | Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 603-615.   | 5.1  | 751       |
| 43 | Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study. <i>European Journal of Cancer</i> , 2018, 105, 114-126.   | 1.3  | 52        |
| 44 | Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. <i>Cancer Science</i> , 2018, 109, 3583-3590.   | 1.7  | 118       |
| 45 | Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.                        | 5.1  | 469       |
| 46 | Sunrise in melanoma management: Time to focus on melanoma burden in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 423-427.   | 0.7  | 23        |
| 47 | Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 651-660.  | 1.1  | 76        |
| 48 | Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. <i>Cancer Science</i> , 2017, 108, 1022-1031.   | 1.7  | 100       |
| 49 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.   | 13.9 | 1,752     |
| 50 | Survivin: A novel marker and potential therapeutic target for human angiosarcoma. <i>Cancer Science</i> , 2017, 108, 2295-2305.   | 1.7  | 23        |
| 51 | Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study. <i>Cancer Science</i> , 2017, 108, 1223-1230.  | 1.7  | 66        |
| 52 | Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy. <i>Oncotarget</i> , 2016, 7, 77404-77415.  | 0.8  | 139       |
| 53 | Phase I study of pegylated interferon- $\alpha$ 2b as an adjuvant therapy in Japanese patients with malignant melanoma. <i>Journal of Dermatology</i> , 2016, 43, 1146-1153.  | 0.6  | 12        |
| 54 | Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 248-253.       | 1.0  | 5         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma with BRAF V600 mutations. <i>Journal of Dermatology</i> , 2015, 42, 661-666.  | 0.6 | 14        |
| 56 | BRAF V600 mutations and pathological features in Japanese melanoma patients. <i>Melanoma Research</i> , 2015, 25, 9-14.   | 0.6 | 43        |
| 57 | Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. <i>Journal of Dermatological Science</i> , 2015, 80, 33-37.  | 1.0 | 87        |
| 58 | Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 463-472.                              | 0.6 | 85        |
| 59 | Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non-Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR). <i>Journal of Thoracic Oncology</i> , 2012, 7, 1296-1303. | 0.5 | 73        |
| 60 | Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update. <i>International Journal of Clinical Oncology</i> , 2008, 13, 33-41.   | 1.0 | 185       |
| 61 | Clinical management of EGFR dermatologic toxicities: the Japanese perspective. <i>Oncology</i> , 2007, 21, 27-8.  | 0.4 | 21        |
| 62 | A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. <i>Cancer Science</i> , 0, , .  | 1.7 | 4         |
| 63 | Postoperative radiation therapy improves prognoses in extramammary Paget's disease presenting with multiple lymph node metastases. <i>Journal of Dermatology</i> , 0, , .   | 0.6 | 0         |